| Literature DB >> 34203608 |
Mina Zare1, Ashkan Bigham2, Mohamad Zare3, Hongrong Luo4, Erfan Rezvani Ghomi1, Seeram Ramakrishna1.
Abstract
Poly(2-hydroxyethyl methacrylate) (pHEMA) as a biomaterial with excellent biocompatibility and cytocompatibility elicits a minimal immunological response from host tissue making it desirable for different biomedical applications. This article seeks to provide an in-depth overview of the properties and biomedical applications of pHEMA for bone tissue regeneration, wound healing, cancer therapy (stimuli and non-stimuli responsive systems), and ophthalmic applications (contact lenses and ocular drug delivery). As this polymer has been widely applied in ophthalmic applications, a specific consideration has been devoted to this field. Pure pHEMA does not possess antimicrobial properties and the site where the biomedical device is employed may be susceptible to microbial infections. Therefore, antimicrobial strategies such as the use of silver nanoparticles, antibiotics, and antimicrobial agents can be utilized to protect against infections. Therefore, the antimicrobial strategies besides the drug delivery applications of pHEMA were covered. With continuous research and advancement in science and technology, the outlook of pHEMA is promising as it will most certainly be utilized in more biomedical applications in the near future. The aim of this review was to bring together state-of-the-art research on pHEMA and their applications.Entities:
Keywords: antimicrobial strategies; biomedical application; cancer therapy; contact lens; ocular drug delivery; pHEMA; tissue engineering and regenerative medicine
Mesh:
Substances:
Year: 2021 PMID: 34203608 PMCID: PMC8232190 DOI: 10.3390/ijms22126376
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Briefly summarizes the biomedical applications of pHEMA, advantages, and disadvantages.
| Biomedical Applications | Advantages | Disadvantages | Reference |
|---|---|---|---|
| Bone tissue generation | Biocompatibility, excellent adhesion-promoting to other polymers, elastomeric properties | Non-degradable, requiring cross-linker | [ |
| Wound healing | Transparency, biocompatibility | Low exudate absorbability, non-degradable, requiring cross-linker | [ |
| Cancer therapy | Stimuli-responsive, inexpensive, easily combined with different polymers and drugs | Non-degradable, requiring cross-linker | [ |
| pHEMA hydrogel contact lens | Inexpensive, biocompatible, abundant copolymer possibilities | protein deposition issues | [ |
Figure 1A schematic representing the synthesis of pHEMA hydrogel from copolymerization of HEMA with other co-monomers, (EGDMA, ethylene glycol dimethacrylate). Reprinted from [27] with permission from Taylor & Francis.
Figure 2A schematic showing the preparation of thermosensitive polymer followed by wound healing (A); the in vivo results of different samples when they were applied on the wounds for 14 days (B); the antibacterial activity of samples against both Staphylococcus aureus and Escherichia coli bacteria (C); ammonium persulfate (APS), radical transformation (RT), poly-(HEMA-co-NIPAM) (PHN), reprinted from [11] with permission from Wiley. ** denotes p < 0.01.
Figure 3A schematic showing different approaches toward drug delivery for cancer therapy—static (A), dynamic (B), and main mechanism for controlling drug release (C). Reprinted from [49] with permission from Elsevier.
Figure 4A schematic of the micelle (A); TEM micrograph of the micelle (B); the release rate of doxorubicin-loaded micelle at physiological and acidic mediums (C); the positron emission tomography images of 4T1 tumor-bearing mice treated with 64Cu-labeled targeted, non-targeted micelles, and targeted micelles with a blocking dose of TRC105 at different time intervals (D). Reprinted from [55] with permission from American Chemical Society.
Figure 5The mechanism of the drug-loaded hydrogen sulfide-responsive micelles when exposed to the stimulant is depicted schematically (A); the drug release rates of the drug-loaded N3-Nap-pHEMA-b-PMMA-N3 sample at acidic and physiological environments, with/without being exposed to hydrogen sulfide (B); the images of HeLa cells treated with doxorubicin (a), drug-loaded N3-Nap-pHEMA-b-PMMA-N3 without hydrogen sulfide (b), and drug-loaded N3-Nap-pHEMA-b-PMMA-N3 with hydrogen sulfide (c), taken by confocal microscopy (scale bar = 20 μm) (C); the cell viability (%) of drug and non-loaded samples, with/without being exposed to hydrogen sulfide (D). Reprinted from [16], with permission from the American Chemical Society.
Figure 6A schematic exhibiting the synthesis procedure of pHEMA-PMMA-magnetite (Fe3O4) (A); the TEM micrographs of the cross-linked pHEMA nanogel (chemically) (a), the cross-linked pHEMA microgel (physically and chemically) (b), Fe3O4-coated cross-linked pHEMA-methotrexate (c), pHEMA-PMMA-Fe3O4 (Janus) (d) (B); the release trends of methotrexate from pHEMA-PMMA-Fe3O4 nanoparticles (C); the magnetic hysteresis loops of bare Fe3O4 and final pHEMA-PMMA-Fe3O4 nanoparticles (a) plus separation of pHEMA-PMMA-Fe3O4 nanoparticles in water by a magnet (b) (D). Reprinted from [15], with permission from the American Chemical Society. (Red arrow: in Figure (b) show coagulation of cross-linked pHEMA nanogel).
Figure 7Schematic representation depicting the difference in drug release time using contact lenses as compared to the conventional topical formulation.
Figure 8Antimicrobial strategies to fabricate microbiocidal contact lenses.
Various approaches and drugs used for contact lens drug delivery.
| No. | Method of Drug Incorporation | Polymers/Contact Lens | Drugs Used | Inference | Ref. |
|---|---|---|---|---|---|
| 1 | Soaking and lyophilization | pHEMA hydrogels containing cross-linked β-cyclodextrin-hyaluronan | Diclofenac | Improved the oxygen permeability, water uptake ability, surface hydrophilicity, and flexibility | [ |
| 2 | Soaking method | HEMA, siloxane, ethylene glycol dimethacrylate, Irgacure®, dimethyl acrylamide | Timolol | Reduce burst release and the timolol retention time improved, the control release kinetics and uptake of timolol improved without varying the transmittance and swelling of the contact lens. | [ |
| 3 | Polymerization of HEMA | HEMA, mPEG-PLA micelles | Latanoprost and Timolol | Improvement in drug residence time and higher bioavailability | [ |
| 4 | Free radical polymerization of the monomer by photoinitiation | pHEMA, chitosan nanoparticles | Dexamethasone Sodium Phosphate | Significantly enhanced bioavailability of ophthalmic drugs | [ |
| 5 | Free radical polymerization technique | pHEMA cross linked dextrin | Ciprofloxacin hydrochloride | Excellent physical stability as carrier for ciprofloxacin up to 3 months | [ |
| 6 | Bioinspired imprinted pHEMA-hydrogels | HEMA, zinc methacrylate, 1- or 4-vinylimidazole, and N-hydroxyethyl acrylamide | Acetazolamide or Ethoxzolamide | Remarkable improvement in the performance as controlled release system | [ |
| 7 | Prepared by photopolymerization | pHEMA, HEMA, mono-methacrylated β-CD (mono-MA-β-CD) and trimethylolpropane trimethacrylate | Puerarin | The data demonstrate that pHEMA/β-CD hydrogel contact lenses can effectively deliver puerarin through the rabbit’s cornea | [ |
| 8 | β-CD was grafted to the gel network and soaked in drug solution | pHEMA and GMA | Diclofenac sodium | The hydrogels with pendant β-CD are particularly useful for the development of cytocompatible drug loaded SCLs | [ |
| 9 | By ultraviolet light polymerization film coating process | PLGA films over pHEMA | Ciprofloxacin, fluorescein | PLGA film coated over pHEMA lenses sustained the release of drug, which can be controlled by changing either the ratio of drug to PLGA or the molecular mass of the PLGA used | [ |
| 10 | Gels prepared by living /controlled imprinting technique | HEMA, acrylic acid, acrylamide and methacrylic acid | Ketotifen, diclofenac sodium | Imprinting via living polymerization extends or delays the template release profile by two-fold over that of imprinting via conventional free-radical polymerization techniques | [ |
| 11 | Dispersion of microemulsion in contact lenses | pHEMA | Hexadecane | p-HEMA gels loaded with a microemulsion, stabilized with silica shell are transparent and releases drugs for a period of over 8 days in vitro | [ |
| 12 | Molecular imprinting technique | HEMA+ methacrylic acid or meth-methacrylate | Timolol | Incorporation of meth-methacrylate as comonomer increases the timolol loading capacity to therapeutically useful levels while retaining appropriate release characteristics in vitro | [ |
| 13 | Molecular imprinting technique | HEMA + methacrylamide propyl trimethylammonium chloride | Azulene | Molecular imprinting is capable to store the anionic drug such as azulene based on ion-exchange reaction | [ |